Andrew Lee is currently an associate professor at the school of chemical biology and biotechnology, Shenzhen Graduate School, Peking University, and holds a joint position at the Shenzhen Bay laboratory Cancer Institute. He studied at Yale University as an undergraduate and received his MD and PhD from Stanford University. Subsequently, Andrew received medical residency training in the clinical pathology department of Stanford Hospital. During this period, he focused on the research of cell / gene therapy and realized the first clinical trial of cell / gene therapy. He has published more than 60 papers on the in-depth research of cell / gene therapy and promoting its entry into new clinical applications.
Andrew Lee's achievements in the field of cell / gene therapy research were published in nature medicine, Nature Biotechnology, nature biomedical engineering, cell, JAMA, circulation and other journals. According to Google academic statistics, he has been cited more than 9000 times with an H-index of 40. In addition, Andrew Lee's research has good application prospects and is supported by the American Heart Association, Howard Hughes Medical Research Institute and the world's top 10 pharmaceutical companies.
1.) Chiang CL, Ma Y, Hou YC, Pan J, Chen SY, Chien MH, Zhang ZX, Hsu WH, Wang X, Zhang J, Li H, Sun L, Fallen S, Lee I, Chen XY, Chu YS, Zhang X, Cheng TS, Jiang W, Kim BYS, Reategui E, Lee R, Yuan Y, Liu HC, Wang K, Hsiao M, Huang CYF#, Shan YS#,Lee AS#, Lee LJ#. Dual targeted extracellular vesicles regulate oncogenic genes in advances pancreatic cancer.Nature Communications 2023;14(1):6692.#=co-corresponding author. Impact Factor = 17.69
2) You Y, Tian Y, Yang Z, Shi J, Kwak KJ, Estania AP, Tong Y, Cao J, Chiang CL, Hsu WH, Liu Y, Shrank B, Huntoon K, lee D, Li Z, Zhao Y, Zhang H, Gallup T, Ha J, Dong S, Lu WJ, Bahrani E, Lee LJ, Teng L, Jiang W, Lan F#, Kim BYS#,Lee AS#. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy.Nature Biomedical Engineering2023;1-13.#=corresponding author. Impact Factor = 29.23
3) Zhao L*,Lee AS*,Sasagawa K*, Sokol J, Wang Y, Ransom RC, Zhao X, Ma C, Steininger HM, Koepke LS, Borrelli MR, Brewer RE, Lee LLY, Huang X, Ambrosi TH, Sinha R, Hoover MY, Seita J, Weissman IL, Wu JC, Wan DC, Xiao J, Longaker MT, Nguyen PK, Chan CKF. Combination of distinct vascular stem / progenitor cells for neovascularization and ischemic rescue.Arteriosclerosis, Thrombosis, and Vascular Biology 2023:https://doi.org/10.1161/ATVBAHA.122.317943. *=equal contribution. Impact Factor = 10.51
4) Li X, Lu WJ, Li Y, Wu F, Bai R, Na S, Dong T, Zhang H,Lee AS#, Wang Y#, Lan F#. MLP-deficient human pluripotent stem cell derived cardiomyocytes develop hypertrophic cardiomyopathy and heart failure phenotypes due to abnormal calcium handling.Cell Death and Disease2019;8(13):1-15.#=co-corresponding author. Impact Factor = 12.07
5) Lee AS*, Inayathullah M*, Lijkwan M*, Zhao X, Sun W, Park S, Hong WX, Parekh M, Malkovskiy, Lau E, Qin X, Pothineni V, Sanchez-Freire V, Zhang W, Kooreman N, Ebert A, Chan C, Nguyen PK, Rajadas J, Wu JC. A novel slow release collagen matrix cross-linked with pro-survival factor analogs promotes stem cell survival for treatment of ischemic cardiovascular disease.Nature Biomedical Engineering2018;2(2):104-113. *=equal contribution
Impact Factor = 29.23
